Literature DB >> 15259900

Infrequent transmission of HIV-1 drug-resistant variants.

Sabine Yerly1, Stéphanie Jost, Amalio Telenti, Markus Flepp, Laurent Kaiser, Jean-Philippe Chave, Pietro Vernazza, Manuel Battegay, Hansjakob Furrer, Bruno Chanzy, Philippe Burgisser, Martin Rickenbach, Martin Gebhardt, Marie-Charlotte Bernard, Thomas Perneger, Bernard Hirschel, Luc Perrin.   

Abstract

Transmission of drug-resistant variants is influenced by several factors, including the prevalence of drug resistance in the population of HIV-1-infected patients, HIV-1 RNA levels and transmission by recently infected patients. In order to evaluate the impact of these factors on the transmission of drug-resistant variants, we have defined the population of potential transmitters and compared their resistance profiles to those of newly infected patients. Sequencing of pol gene was performed in 220 recently infected patients and in 373 chronically infected patients with HIV-1 RNA >1000 copies/ml. Minimal and maximal drug-resistance profiles of potential transmitters were estimated by weighting resistance profiles of chronically infected patients with estimates of the Swiss HIV-1-infected population, the prevalence of exposure to antiviral drugs and the proportion of infections attributed to primary HIV infections. The drug-resistance prevalence in recently infected patients was 10.5% (one class drug resistance: 9.1%; two classes: 1.4%; three classes: 0%). Phylogenetic analysis revealed significant clustering for 30% of recent infections. The drug-resistance prevalence in chronically infected patients was 72.4% (one class: 29%; two classes: 27.6%; three classes: 15.8%). After adjustment, the risk of transmission relative to wild-type was reduced both for one class drug resistance (minimal and maximal estimates: odds ratio: 0.39, P<0.001; and odds ratio: 0.55, P=0.011, respectively), and for two to three class drug resistance (odds ratios: 0.05 and 0.07, respectively, P<0.001). Neither sexual behaviour nor HIV-1 RNA levels explained the low transmission of drug-resistant variants. These data suggest that drug-resistant variants and in particular multidrug-resistant variants have a substantially reduced transmission capacity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15259900

Source DB:  PubMed          Journal:  Antivir Ther        ISSN: 1359-6535


  19 in total

1.  The use of highly active retroviral therapy to reduce HIV incidence at the population level.

Authors:  Aranka Anema; Evan Wood; Julio S G Montaner
Journal:  CMAJ       Date:  2008-07-01       Impact factor: 8.262

2.  Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.

Authors:  Philippe Selhorst; Ana C Vazquez; Katty Terrazas-Aranda; Johan Michiels; Katleen Vereecken; Leo Heyndrickx; Jan Weber; Miguel E Quiñones-Mateu; Kevin K Ariën; Guido Vanham
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

3.  How HIV treatment could result in effective prevention.

Authors:  Kartik K Venkatesh; Mark N Lurie; Kenneth H Mayer
Journal:  Future Virol       Date:  2010-07       Impact factor: 1.831

4.  Dynamics of haplotype frequency change in a CD8+TL epitope of simian immunodeficiency virus.

Authors:  Austin L Hughes; Shelby O'Connor; Dawn M Dudley; Benjamin J Burwitz; Benjamin N Bimber; David O'Connor
Journal:  Infect Genet Evol       Date:  2010-02-10       Impact factor: 3.342

Review 5.  Resilience to resistance of HIV-1 protease inhibitors: profile of darunavir.

Authors:  Eric Lefebvre; Celia A Schiffer
Journal:  AIDS Rev       Date:  2008 Jul-Sep       Impact factor: 2.500

6.  Persistence of transmitted drug resistance among subjects with primary human immunodeficiency virus infection.

Authors:  Susan J Little; Simon D W Frost; Joseph K Wong; Davey M Smith; Sergei L Kosakovsky Pond; Caroline C Ignacio; Neil T Parkin; Christos J Petropoulos; Douglas D Richman
Journal:  J Virol       Date:  2008-03-19       Impact factor: 5.103

Review 7.  Clinical significance of human immunodeficiency virus type 1 replication fitness.

Authors:  Carrie Dykes; Lisa M Demeter
Journal:  Clin Microbiol Rev       Date:  2007-10       Impact factor: 26.132

8.  Factors influencing the emergence and spread of HIV drug resistance arising from rollout of antiretroviral pre-exposure prophylaxis (PrEP).

Authors:  Ume L Abbas; Gregory Hood; Arthur W Wetzel; John W Mellors
Journal:  PLoS One       Date:  2011-04-15       Impact factor: 3.240

9.  More than 30% HCV prevalence in the HIV-1 El-Fateh children hospital outbreak is a key for both elucidation and public health measures.

Authors:  Luc Perrin
Journal:  Libyan J Med       Date:  2007-06-01       Impact factor: 1.657

10.  X4 tropic multi-drug resistant quasi-species detected at the time of primary HIV-1 infection remain exclusive or at least dominant far from PHI.

Authors:  Jade Ghosn; Julie Galimand; Stéphanie Raymond; Laurence Meyer; Christiane Deveau; Cécile Goujard; Jacques Izopet; Christine Rouzioux; Marie-Laure Chaix
Journal:  PLoS One       Date:  2011-08-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.